Edition:
United Kingdom

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

163.03USD
19 Sep 2018
Change (% chg)

-- (--)
Prev Close
$163.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
192,929
52-wk High
$183.96
52-wk Low
$128.58

Latest Key Developments (Source: Significant Developments)

Vyxeos Receives Marketing Authorisation In EU For Treatment Of Certain Types Of High-Risk Acute Myeloid Leukaemia
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Jazz Pharmaceuticals PLC ::VYXEOS® RECEIVES MARKETING AUTHORISATION IN THE EUROPEAN UNION FOR TREATMENT OF CERTAIN TYPES OF HIGH-RISK ACUTE MYELOID LEUKAEMIA.JAZZ PHARMACEUTICALS PLC - EUROPEAN COMMISSION APPROVAL EXTENDS TO ALL EUROPEAN UNION MEMBER STATES, AS WELL AS ICELAND, NORWAY AND LIECHTENSTEIN.JAZZ PHARMACEUTICALS -PHASE 3 STUDY MET ITS PRIMARY ENDPOINT AS VYXEOS DEMONSTRATED SUPERIOR IMPROVEMENT IN OVERALL SURVIVAL COMPARED TO 7+3 TREATMENT REGIMEN.  Full Article

Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $3.49.Q2 GAAP EARNINGS PER SHARE $1.50.Q2 REVENUE $500 MILLION VERSUS I/B/E/S VIEW $469.9 MILLION.Q2 EARNINGS PER SHARE VIEW $3.23 -- THOMSON REUTERS I/B/E/S.SEES FULL YEAR 2018 REVENUES $1,880 MILLION -$1,930 MILLION.SEES FULL YEAR 2018 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $12.75-$13.25.SEES FULL YEAR 2018 GAAP NET INCOME PER DILUTED SHARE $5.70-$6.90.FY2018 EARNINGS PER SHARE VIEW $13.09, REVENUE VIEW $1.90 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Jazz Pharmaceuticals And MD Anderson Cancer Center Collaborate To Evaluate Potential Treatment Options For Hematologic Malignancies
Monday, 6 Aug 2018 

Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS AND MD ANDERSON CANCER CENTER COLLABORATE TO EVALUATE POTENTIAL TREATMENT OPTIONS FOR HEMATOLOGIC MALIGNANCIES.  Full Article

Jazz Pharmaceuticals Enters Into Agreement With Tersera Therapeutics For Prialt
Friday, 29 Jun 2018 

June 29 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ENTERS INTO AGREEMENT WITH TERSERA THERAPEUTICS LLC FOR PRIALT.JAZZ PHARMACEUTICALS PLC - DEAL FOR $80 MILLION IN CASH AT CLOSING.JAZZ PHARMACEUTICALS PLC - TERSERA WILL OFFER EMPLOYMENT POSITIONS TO A MAJORITY OF JAZZ EMPLOYEES DEDICATED TO PRIALT.  Full Article

Jazz Pharmaceuticals Announces FDA Acceptance Of Supplemental New Drug Application For Xyrem (Sodium Oxybate)
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR XYREM® (SODIUM OXYBATE) TO TREAT CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC NARCOLEPSY PATIENTS.PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE FOR AN FDA DECISION IS OCTOBER 27, 2018.  Full Article

Spark Therapeutics Says Entered Into Asset Purchase Agreement With Jazz Pharmaceuticals Ireland Ltd
Monday, 30 Apr 2018 

April 30 (Reuters) - Spark Therapeutics Inc ::SPARK THERAPEUTICS SAYS ENTERED INTO ASSET PURCHASE AGREEMENT WITH JAZZ PHARMACEUTICALS IRELAND LIMITED - SEC FILING.SPARK THERAPEUTICS - PURSUANT TO AGREEMENT CO AGREED TO SELL RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER.SPARK THERAPEUTICS - JAZZ WILL PAY CO $110 MILLION FOR PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER UPON CLOSING OF PURCHASE - SEC FILING.  Full Article

Jazz Pharma Submits New Drug Application For Solriamfetol (JZP-110)
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Jazz Pharmaceuticals Plc ::JAZZ PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION FOR SOLRIAMFETOL (JZP-110) FOR EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY AND OBSTRUCTIVE SLEEP APNEA.JAZZ PHARMACEUTICALS PLC - SUBMISSION OF NDA TO U.S. FDA SEEKING MARKETING APPROVAL FOR SOLRIAMFETOL.  Full Article

Pfenex Earns $18.5 Million In Milestones And Updates Worldwide License And Option Agreement With Jazz Pharma
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Pfenex Inc ::PFENEX EARNS $18.5 MILLION IN MILESTONES AND UPDATES WORLDWIDE LICENSE AND OPTION AGREEMENT WITH JAZZ PHARMACEUTICALS.PFENEX INC - UNDER AMENDED AGREEMENT, PFENEX WILL BE ELIGIBLE TO RECEIVE AN ADDITIONAL $43.5 MILLION IN AMENDMENT FEE AND DEVELOPMENT MILESTONE PAYMENTS.PFENEX INC - AMENDMENT OF 2016 DEAL THAT GRANTED JAZZ PHARMA RIGHTS TO DEVELOP & COMMERCIALIZE MULTIPLE EARLY STAGE HEMATOLOGY PRODUCT CANDIDATES.  Full Article

Jazz Pharmaceuticals posts Q3 EPS of $1.03
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Jazz Pharmaceuticals Plc :Jazz pharmaceuticals announces third quarter 2017 financial results.Q3 adjusted earnings per share $3.22.Q3 GAAP earnings per share $1.03.Q3 earnings per share view $2.89 -- Thomson Reuters I/B/E/S.Qtrly ‍total revenues $411.9 million versus $374.2 million.Q3 revenue view $420.4 million -- Thomson Reuters I/B/E/S.Sees ‍FY 2017 revenues $1,600 million -$1,650​ million.Sees FY 2017 ‍gaap net income per diluted share $5.30-$6.30​.Sees ‍FY 2017 non-GAAP adjusted net income per diluted share $10.70-$11.20​.FY 2017 earnings per share view $10.89, revenue view $1.64 billion -- Thomson Reuters I/B/E/S.  Full Article

ELSALYS BIOTECH ACQUIRES FROM JAZZ PHARMA WORLDWIDE RIGHTS OF LEUKOTAC
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Elsalys Biotech::ELSALYS BIOTECH ACQUIRES FROM JAZZ PHARMACEUTICALS THE WORLDWIDE RIGHTS OF LEUKOTAC.‍ELSALYS BIOTECH SAYS HAS INITIATED DISCUSSION WITH EUROPEAN HEALTH AUTHORITIES AND WILL ENGAGE IN REGULATORY INTERACTIONS WITH FDA IN 2018​.  Full Article

UPDATE 2-U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

July 13 A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine.